<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> of worldwide increased incidence </plain></SENT>
<SENT sid="1" pm="."><plain>The vast majority of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cases occur in patients older than age 50 </plain></SENT>
<SENT sid="2" pm="."><plain>The initial stage at the time of diagnosis has a strong influence on the overall survival (OS) </plain></SENT>
<SENT sid="3" pm="."><plain>According to AJCC sixth edition system, 5-year stage-specific survivals are over 90% in stage I, but only approximately 8% in stage IV [1] </plain></SENT>
<SENT sid="4" pm="."><plain>Chemotherapy in combination with biological treatment has improved response rates (RR), with prolongation of progression free survival (PFS) and OS </plain></SENT>
<SENT sid="5" pm="."><plain>Important role in treatment of metastatic colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (mCRC) plays surgical resection of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Multidisciplinary cooperation between medical oncologist, surgeon, radiologist and radiotherapist is necessary to achieve the best therapeutic results </plain></SENT>
<SENT sid="7" pm="."><plain>The aim of our analysis was to describe the efficacy of bevacizumab used in combination with chemotherapy in the first-line setting and to evaluate frequency of thromboembolic complications during the treatment </plain></SENT>
<SENT sid="8" pm="."><plain>The analysis included 58 patients with mCRC, who have been treated with first-line chemotherapy in combination with bevacizumab at the St </plain></SENT>
<SENT sid="9" pm="."><plain>Elizabeth <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Institute in Bratislava since 2006 and first assessed for the first therapeutic results in October 2010 </plain></SENT>
<SENT sid="10" pm="."><plain>The clinical benefit after the treatment represented by overall response rate (ORR) and stable disease (SD) was achieved in 87.93% of patients, and surgical resection of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> after therapy underwent 12.07% of patients </plain></SENT>
<SENT sid="11" pm="."><plain>Median time to progression (<z:chebi fb="1" ids="18284">TTP</z:chebi>) was 8 months and median OS evaluated in October 2011 was 27 months </plain></SENT>
<SENT sid="12" pm="."><plain>Mutation status of KRAS gene had no influence on the effectiveness of treatment and BRAF mutations exhibited a strong negative prognostic significance </plain></SENT>
<SENT sid="13" pm="."><plain>Thromboembolic complications were present in 17.24% </plain></SENT>
<SENT sid="14" pm="."><plain>Keywords: metastatic colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp>, first-line treatment, biological treatment, molecular markers, bevacizumab-related toxicity </plain></SENT>
</text></document>